GeoVax Expands Atlanta Presence to Accelerate Cancer and Vaccine Development

GeoVax Labs, Inc., a clinical-stage biotechnology company trading on Nasdaq under GOVX, has announced significant relocations of both its corporate headquarters and laboratory operations to new facilities in the Atlanta metropolitan area, scheduled for completion in the fourth quarter of 2025. The laboratory group will move to Science Square / Portal Innovations in midtown Atlanta, providing expanded access to state-of-the-art laboratories and collaborative research environments designed to accelerate innovation. Meanwhile, the corporate headquarters will establish a new hub at 1955 Lake Park Drive in Smyrna, Georgia, strengthening the company's administrative capabilities and leadership functions. These strategic moves position GeoVax for accelerated growth and market readiness as it advances its expanding pipeline of immunotherapies and multi-antigen vaccines targeting cancers and infectious diseases.

According to David Dodd, Chairman and Chief Executive Officer of GeoVax, these relocations represent a significant milestone in the company's evolution, placing the R&D team within one of the most dynamic bio-research ecosystems in the Southeast while expanding the administrative base to support broader operations. The company's pipeline includes the promising GEO-MVA program and multiple clinical trials in cancer therapy and infectious disease vaccines. Eddie Lai, Director of Business Development at Atlanta Portal Innovations, expressed excitement about GeoVax joining their ecosystem, noting that the company brings a strong legacy of innovation rooted in the Southeast to an innovation engine that supports over 100 scientific companies across the country. The relocations underscore GeoVax's trajectory toward long-term growth, scientific advancement, and future commercialization opportunities, with enhanced infrastructure providing a strong foundation to meet global healthcare needs.

GeoVax's lead clinical programs include GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, a booster for chronic lymphocytic leukemia patients, and a more robust booster for healthy patients who previously received mRNA vaccines. In oncology, the company is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Additionally, GeoVax is developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to Phase 3 clinical evaluation. For more information about current clinical trials and updates, visit www.geovax.com, where investors and interested parties can find detailed information about the company's progress and technological innovations.